Table 4

The use of disease modifying antirheumatic drugs and anti-TNF treatment in 338 patients with psoriatic arthritis

Male (n=144)Female (n=194)p Value
Methotrexate
 Never (%)71 (49.3)91 (46.9)0.61
 Ever (%)69 (50.7)99 (51.1)
  Previous (%)20 (13.9)43 (22.2)
  Current (%)49 (34.0)56 (28.9)
NA (%)4 (2.8)4 (2.1)
Leflunomide
 Never (%)126 (87.5)150 (77.3)0.03*
 Ever (%)18 (12.5)46 (23.7)
  Previous (%)10 (6.9)29 (14.9)
  Current (%)8 (5.6)17 (8.8)
Sulfasalazine
 Never (%)133 (92.4)169 (91.8)0.66
 Ever (%)9 (6.3)16 (8.2)
  Previous (%)6 (4.2)14 (7.2)
  Current (%)3 (2.1)2 (1.0)
NA (%)2 (1.4)9 (4.6)
Anti-TNF treatment
 Never (%)126 (87.5)149 (76.8)0.01*
 Ever (%)18 (12.5)45 (23.2)
  Previous (%)3 (2.1)18 (9.3)
  Current (%)15 (10.4)27 (13.9)
  • Statistics are performed between ever users (previous and current) versus never users.

  • * p <0.05.

  • NA, not available.